QQQI: The Income Feels Good, But The Bear Market Won't
NEOS Nasdaq-100 High Income ETF is structurally flawed, offering high yield but exposing investors t…
seekingalpha.com
AVXL(AVXL)
AVXL
Earnings in 3 days · May 19, 2026 · Before open
Signal
Bearish Setup2↓
PRICE
Prev Close
3.08
Open
3.04
Day Range2.89 – 3.06
2.89
3.06
52W Range2.61 – 13.99
2.61
13.99
3% of range
VOLUME & SIZE
Avg Volume
1.3M
FUNDAMENTALS
P/E Ratio
-6.3x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.90
High vol
Performance
1D
-5.52%5D
-6.73%1M
-10.19%3M
-25.95%6M
-20.27%YTD
-18.26%1Y↓
-65.23%Worst: 1Y (-65.23%)
Quick Read
Trend—Insufficient MA data
Momentum
BEARISH
thin 0% gross marginValuation
FAIR
P/E not availableHealth
MODERATE
CR 20.9 · FCF negativeNeutral
Key MetricsTTM
Market Cap$269.67M
Revenue TTM$0.00
Net Income TTM-$39.95M
Free Cash Flow-$34.08M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity-38.8%
Return on Assets-30.0%
Debt / Equity0.00
Current Ratio20.87
EPS TTM$-0.45
Alpha SignalsView Intelligence →
Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.
Health Radar
3 strong3 concern
50/100Liquidity
20.87Strong
Leverage
0.00Strong
Coverage
0.0xConcern
ROE
-38.8%Concern
ROIC
-35.2%Concern
Cash
$103MStrong
ANALYST COVERAGE13 analysts
BUY
▲ +278.0%upside to target
Stock Health
Composite Score
3 of 5 signals bullish
5/10
Technicals
●
✗RSI RangeRSI 41 — Bearish momentum
Volume
●
✗Volume FlowDistribution — institutional selling
Fundamentals
●
✓Last EarningsBeat estimates
●
✓Analyst ConsensusBuy
●
✓LiquidityCurrent Ratio 20.87 — healthy liquidity
Upcoming Events
EEarnings ReportMay 17, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 90 days
PDividend PaymentSep 10, 2026
In 117 days
FinancialsFull statements →
Technicals
Technical SetupBEARISH
Technicals →Trend
▼ DowntrendDeath Cross · 50D trails 200D by 41.8%
-24.1% vs SMA 50 · -55.8% vs SMA 200
Momentum
RSI40.6Momentum fading
MACD-0.21Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$13.99+380.8%
EMA 200
$6.28+115.8%
EMA 50
$3.69+26.9%
Current
$2.91
52W Low
$2.61-10.3%
52-Week RangeNear 52-week low
$2.613th %ile$13.99
Squeeze SetupVolume-based
Distribution PressureDistribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
20-Day Money Flow
Acc days:0
Dist days:0
Edge:Even
Volume Context
Avg Vol (50D)1.4M
Recent Vol (5D)
1.2M-15%
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
Earnings & Analysts
ANALYST ESTIMATES
Consensus of 2 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $14.4M $14.4M–$14.4M | — | -$0.58 | — | — | Low2 |
FY2026(current) | $776.0M $776.0M–$776.0M | ▲ +5297.1% | -$0.33 | — | — | Low2 |
FY2027 | $1.2B $1.2B–$1.2B | ▲ +55.9% | -$0.14 | — | — | Low2 |
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryAVXL
Last 8Q
+11.6%avg beat
Beat 6 of 8 quartersMissed 1↑ Estimates rising—
Q2'24
+7%
Q3'24
+18%
Q4'24
+18%
Q1'25
+19%
Q2'25
-23%
Q3'25
+15%
Q4'25
+40%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced heightInsider Activity
SEC Filings →2 Buys/4 SellsNet Selling
Donhauser Peter D.o.Dir
$10K
Jun 14
BUY
Thomas SteffenDir
$23K
May 15
BUY
Missling Christophe…Dir
$375K
Mar 28
SELL
Missling Christophe…Dir
$2.1M
Jun 28
SELL
Skarpelos AthanasiosDir
$453K
May 25
SELL
Missling Christophe…Dir
$1.3M
Jun 29
SELL
Financials
INSTITUTIONAL OWNERSHIP
1
BlackRock, Inc.
7.6M▲2
STATE STREET CORP
4.5M▲3
TWO SIGMA INVESTMENTS, LP
3.2M▲4
GEODE CAPITAL MANAGEMENT, LLC
2.2M▲5
SUSQUEHANNA INTERNATIONAL GROUP, LLP
996K▲6
Summit Financial, LLC
940K▲7
GOLDMAN SACHS GROUP INC
804K▼8
AQR CAPITAL MANAGEMENT LLC
757K▲News & Activity
AVXL News
20 articles · 4h ago
Realty Income: Raised Guidance, Higher Growth Expectations Reinforces The Bull Case For Income Investors
seekingalpha.com
VPU: Utilities Dashboard For May
seekingalpha.com
Peloton Stock Gives Back Gains After Upbeat Earnings Report
marketbeat.com
Buy Nvidia Under $250 on Trump's China Visit and Warsh's Dovish AI Signals
247wallst.com
High Liner Foods Q1 Earnings Call Highlights
marketbeat.com
i-80 Gold Q1 Earnings Call Highlights
marketbeat.com
Gunnison Copper appoints Craig Hallworth as CEO - ICYMI
proactiveinvestors.com
Bayanat Engineering Brings Advanced Meteorological Sensing to Dubai's First Commercial eVTOL Vertiport
globenewswire.com
Alpine Income Property: Why This 6.4% Yield Has Upside Potential
seekingalpha.com
Creator content made the main stage at TV's 'upfront' pitches — and not just for YouTube
cnbc.com
Cerebras' blockbuster IPO boosts hype for SpaceX and OpenAI, but crowds out smaller players
cnbc.com
Black Rock Coffee Bar Continues Expansion in Phoenix with Two New Locations
globenewswire.com
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
globenewswire.com
VVC Exploration Corporation Announces Application For Management Cease Trade Order And Provides Financing Update
globenewswire.com
The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Sun Communities, Inc. Publicly-Traded Common Stock - SUI
globenewswire.com
Black Rock Coffee Bar Continues Expansion in Phoenix with Two New Locations
globenewswire.com
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
globenewswire.com
VVC Exploration Corporation Announces Application For Management Cease Trade Order And Provides Financing Update
globenewswire.com
Schwab Remains Highly Attractive
seekingalpha.com
About
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Christopher Missling
Website
Juan Carlos Lopez-TalaveraSenior Vice President & Head of Research and Development
Kun JinVice President & Head of Biostatistics
Clint TomlinsonVice President of Corporate
Peers— Health Care(7 companies)
Screen sector →| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
AVXL◀ | $2.91 | -5.52% | $270M | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.33% | — | 50.3 | +398824.8% | -4085.6% | 1500 |